NCT05487248Completed
A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
Source: ClinicalTrials.gov · Last updated 25 Aug 2026
Brief summary (registry, in English)
COPERNIC is an international, multicentre, single-arm study. Chemo-refractory mCRC subjects who meet all eligibility criteria will be treated with standard systemic chemotherapy (the decision about the treatment regimen being made by the treating physician) and undergo tumour assessment by standard imaging (either CT scan or MRI scan) at baseline and every 8 or 12 weeks until evidence of tumour progression. Response to treatment will be assessed by the local investigators according to the RECIST criteria version 1.1. Blinded, independent central review of the imaging scan will be carried out, this having no impact on treatment decisions thatwhich will remain the prerogative of the treating physician. Serial blood samples from study subjects will be collected at pre-defined time points for ctDNA testing. Also, archived tumour tissue from each subject will be collected. Prospective and retrospective ctDNA analyses on blood samples will be carried out, and dynamics of ctDNA will be correlated with treatment outcomes prognosis.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 103 (actual)
- First submitted
- 27 May 2022
- Start date
- 12 Oct 2023
- Primary completion date
- 24 Aug 2026
- Lead sponsor
- Jules Bordet Institute
- Diseases
- Colorectal cancer
- NCT number
- NCT05487248
What you commit to
- Study type: Interventional
- Participants enrolled: 103
- From 12 Oct 2023 to the primary completion date, 24 Aug 2026
- 12 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Tumours other than colorectal cancer
- Any baseline medical condition that would contraindicate the use of systemic chemotherapy or may preclude the regular administration of the same
- Any psychiatric condition that would prohibit the understanding or rendering of informed consent
- Other invasive malignancy within 3 years except for non-invasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has/have been surgically cured
- Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study.
Other
- Histologies other than adenocarcinoma
- Pregnant and/ or lactating women
- Exclusion criterion applicable to FRANCE only
- Vulnerable persons according to the article L.1121-6 of the Public Health Code, adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the Public Health Code.
Who the study is looking for
- Age ≥ 18 years old
- Male or female
- ECOG performance status ≤2
- Must have histologically or cytologically verified colorectal cancer adenocarcinoma
- Inoperable locally advanced or metastatic disease
- Presence of measurable disease (by RECIST criteria version 1.1) on baseline CT scan of the thorax/abdomen/pelvis or CT scan of the thorax and MRI of the abdomen/pelvis
- At least two prior systemic treatments for advanced/metastatic colorectal cancer including oxaliplatin and irinotecan-based therapy (adjuvant or neoadjuvant systemic chemotherapy will be considered if tumour progression was documented within 6 month of the last chemotherapy dose)
- Candidate for standard third-line or subsequent lines of therapy as per decision of the treating physician
- Life expectancy of at least 3 months
- Women of childbearing potential must have a negative serum pregnancy test done within 28 days prior to enrolment.
- Effective contraception is in place for women of childbearing potential.
- Completion of all necessary screening procedures within 28 days prior to enrolment.
- Availability of archived tumour tissue
- Signed Informed Consent form (ICF) obtained prior to any study related procedure.
- Inclusion criterion applicable to FRANCE only
- Affiliated to the French Social Security System
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Jules Bordet Coordinator of this site? Confirm its status | Anderlecht | Belgium | Unknown status |
| UZ Antwerpen Coordinator of this site? Confirm its status | Antwerp | Belgium | Unknown status |
| Chirec Delta Coordinator of this site? Confirm its status | Brussels | Belgium | Unknown status |
| CHU Ambroise Paré Coordinator of this site? Confirm its status | Mons | Belgium | Unknown status |
| Cliniques universitaires Saint-Luc Coordinator of this site? Confirm its status | Woluwe-Saint-Lambert | Belgium | Unknown status |
| Centre Georges François Leclerc Coordinator of this site? Confirm its status | Dijon | France | Unknown status |
| Hopital Franco-Britannique - Fondation Cognacq-Jay Coordinator of this site? Confirm its status | Levallois-Perret | France | Unknown status |
| Hôpital Privé Jean Mermoz Coordinator of this site? Confirm its status | Lyon | France | Unknown status |
| Hopital St-Louis Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| CHU Poitiers Coordinator of this site? Confirm its status | Poitiers | France | Unknown status |
| ICO Saint-Herblain Coordinator of this site? Confirm its status | Saint-Herblain | France | Unknown status |
| ICANS Strasbourg Coordinator of this site? Confirm its status | Strasbourg | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.